Shawn He
Chief Scientific Officer JW Therapeutics
Shawn He, PhD, is Chief Scientific Officer at JW Therapeutics. Prior to joining JW, he served as CSO at Cure Genetics, where he built a CAR-NKT pipeline for solid tumors. Previously, he was EVP of R&D at Celularity, leading development of novel allogeneic CAR-T and CAR-NK therapies. Earlier, Dr. He held roles of increasing responsibility at Celgene Cellular Therapeutics, advancing three cell therapy programs into IND-enabling studies, all of which entered the clinic across eight indications. He received his PhD from the University of Maryland, College Park.
Seminars
- Implementing phase-appropriate comparability strategies from phase one through phase three to maintain product consistency while transitioning from manual to automated processing
- Navigating critical process changes including automation of culture operations to balance regulatory expectations with commercial manufacturing scalability and cost effectiveness
- Establishing robust comparability frameworks early in development to prevent late-stage regulatory setbacks when integrating closed automated systems for commercial transition
Starting material limitations and quality issues pose significant risks to cell therapy
process development, yet is often identified too late. Donor-to-donor variability,
cryopreservation losses, and inadequate material for analytical validation create
bottlenecks across functions. Join this workshop to discuss strategies for classifying
donors, optimizing cell recovery post-thaw, addressing media composition challenges,
and ensuring cross-functional teams have sufficient high-quality material for both
process development and analytical testing.
This workshop will gather experts to discuss:
- Optimizing cryopreservation and thawing protocols to minimize cell loss and maintain viability for consistent downstream processing
- Classifying donors and implementing manufacturing adaptations based on variability to control process parameters and ensure product quality
- Addressing cell culture media composition uncertainties and logistical challenges to improve starting material consistency across disease indications
- Coordinating between process development and analytical teams to secure sufficient quality material for validation, qualification, and robust testing
